Cargando…
Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer
Chinese formulas have been paid increasing attention in cancer multidisciplinary therapy due to their multi-targets and multi-substances property. Here, we aim to investigate the anti-breast cancer and chemosensitizing function of Ai Du Qing (ADQ) formula made up of Hedyotis diffusa, Curcuma zedoari...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176282/ https://www.ncbi.nlm.nih.gov/pubmed/30333750 http://dx.doi.org/10.3389/fphar.2018.01106 |
_version_ | 1783361669402984448 |
---|---|
author | Wang, Neng Yang, Bowen Zhang, Xiaotong Wang, Shengqi Zheng, Yifeng Li, Xiong Liu, Shan Pan, Hao Li, Yingwei Huang, Zhujuan Zhang, Fengxue Wang, Zhiyu |
author_facet | Wang, Neng Yang, Bowen Zhang, Xiaotong Wang, Shengqi Zheng, Yifeng Li, Xiong Liu, Shan Pan, Hao Li, Yingwei Huang, Zhujuan Zhang, Fengxue Wang, Zhiyu |
author_sort | Wang, Neng |
collection | PubMed |
description | Chinese formulas have been paid increasing attention in cancer multidisciplinary therapy due to their multi-targets and multi-substances property. Here, we aim to investigate the anti-breast cancer and chemosensitizing function of Ai Du Qing (ADQ) formula made up of Hedyotis diffusa, Curcuma zedoaria (Christm.) Rosc., Astragalus membranaceus (Fisch.) Bunge, and Glycyrrhiza uralensis Fisch. Our findings revealed that ADQ significantly inhibited cell proliferation in both parental and chemo-resistant breast cancer cells, but with little cytotoxcity effects on the normal cells. Besides, ADQ was found to facilitate the G2/M arresting and apoptosis induction effects of paclitaxel. Network pharmacology and bioinformatics analysis further demonstrated that ADQ yielded 132 candidate compounds and 297 potential targets, and shared 22 putative targets associating with breast cancer chemoresponse. Enrichment analysis and experimental validation demonstrated that ADQ might improve breast cancer chemosensitivity via inhibiting caveolin-1, which further triggered expression changes of cell cycle-related proteins p21/cyclinB1 and apoptosis-associated proteins PARP1, BAX and Bcl-2. Besides, ADQ enhanced in vivo paclitaxel chemosensitivity on breast cancer. Our study not only uncovers the novel function and mechanisms of ADQ in chemosensitizing breast cancer at least partly via targeting caveolin-1, but also sheds novel light in utilizing network pharmacology in Chinese Medicine research. |
format | Online Article Text |
id | pubmed-6176282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61762822018-10-17 Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer Wang, Neng Yang, Bowen Zhang, Xiaotong Wang, Shengqi Zheng, Yifeng Li, Xiong Liu, Shan Pan, Hao Li, Yingwei Huang, Zhujuan Zhang, Fengxue Wang, Zhiyu Front Pharmacol Pharmacology Chinese formulas have been paid increasing attention in cancer multidisciplinary therapy due to their multi-targets and multi-substances property. Here, we aim to investigate the anti-breast cancer and chemosensitizing function of Ai Du Qing (ADQ) formula made up of Hedyotis diffusa, Curcuma zedoaria (Christm.) Rosc., Astragalus membranaceus (Fisch.) Bunge, and Glycyrrhiza uralensis Fisch. Our findings revealed that ADQ significantly inhibited cell proliferation in both parental and chemo-resistant breast cancer cells, but with little cytotoxcity effects on the normal cells. Besides, ADQ was found to facilitate the G2/M arresting and apoptosis induction effects of paclitaxel. Network pharmacology and bioinformatics analysis further demonstrated that ADQ yielded 132 candidate compounds and 297 potential targets, and shared 22 putative targets associating with breast cancer chemoresponse. Enrichment analysis and experimental validation demonstrated that ADQ might improve breast cancer chemosensitivity via inhibiting caveolin-1, which further triggered expression changes of cell cycle-related proteins p21/cyclinB1 and apoptosis-associated proteins PARP1, BAX and Bcl-2. Besides, ADQ enhanced in vivo paclitaxel chemosensitivity on breast cancer. Our study not only uncovers the novel function and mechanisms of ADQ in chemosensitizing breast cancer at least partly via targeting caveolin-1, but also sheds novel light in utilizing network pharmacology in Chinese Medicine research. Frontiers Media S.A. 2018-10-02 /pmc/articles/PMC6176282/ /pubmed/30333750 http://dx.doi.org/10.3389/fphar.2018.01106 Text en Copyright © 2018 Wang, Yang, Zhang, Wang, Zheng, Li, Liu, Pan, Li, Huang, Zhang and Wang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wang, Neng Yang, Bowen Zhang, Xiaotong Wang, Shengqi Zheng, Yifeng Li, Xiong Liu, Shan Pan, Hao Li, Yingwei Huang, Zhujuan Zhang, Fengxue Wang, Zhiyu Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer |
title | Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer |
title_full | Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer |
title_fullStr | Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer |
title_full_unstemmed | Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer |
title_short | Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer |
title_sort | network pharmacology-based validation of caveolin-1 as a key mediator of ai du qing inhibition of drug resistance in breast cancer |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176282/ https://www.ncbi.nlm.nih.gov/pubmed/30333750 http://dx.doi.org/10.3389/fphar.2018.01106 |
work_keys_str_mv | AT wangneng networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer AT yangbowen networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer AT zhangxiaotong networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer AT wangshengqi networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer AT zhengyifeng networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer AT lixiong networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer AT liushan networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer AT panhao networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer AT liyingwei networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer AT huangzhujuan networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer AT zhangfengxue networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer AT wangzhiyu networkpharmacologybasedvalidationofcaveolin1asakeymediatorofaiduqinginhibitionofdrugresistanceinbreastcancer |